Advanced glycation end-product (AGE) cross-link breakers represent a potential future therapeutic target for isolated systolic hypertension and diastolic heart failure.
No takes yet. Share an insight, caveat, or question.
AGE cross-link breakers merit human trials in isolated systolic hypertension and HFpEF; evidence remains preclinical and hypothesis-generating.
Doron Aronson (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: